Neurocrine Biosciences, Inc.
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): December 20, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-22705   33-0525145
(State or other   (Commission File   (IRS Employer Identification
jurisdiction of   Number)   No.)
incorporation or        
organization)        
     
12790 El Camino Real   92130
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
 

 


TABLE OF CONTENTS

ITEM 8.01 OTHER EVENTS
Item 9.01. Exhibits
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

ITEM 8.01 OTHER EVENTS.
On December 20, 2006, the Company announced that under the collaboration between Neurocrine and GlaxoSmithKline (GSK), GSK has initiated Phase II “proof of concept” clinical trials with a lead Corticotropin Releasing Factor R1 (CRF1) receptor antagonist compound for two indications, social anxiety disorder (SocAD) and irritable bowel syndrome (IBS). As a result, the Company has recognized an $8 million milestone payment from GSK upon initiation of these two Phase II clinical trials.
Item 9.01. Exhibits
99.1   Press release dated December 20, 2006.

 


Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
Dated: December 20, 2006
  NEUROCRINE BIOSCIENCES, INC.    
 
       
 
  /s/ Timothy P. Coughlin
 
Timothy P. Coughlin
   
 
  Vice President and Chief Financial Officer    

 


Table of Contents

EXHIBIT INDEX
     
Exhibit    
Number   Document Description
99.1
  Press release dated December 20, 2006